Cyclooxygenase inhibitors and cardiovascular risk [4]

JAMA

Volumn 297, Issue 6, 2007, Pages 586-587

  Andersohn, Frank ^a   Suissa, Samy ^b   Garbe, Edeltraut ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CELECOXIB; CYTOCHROME P450 2C9; ETORICOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB;

ACUTE HEART INFARCTION; ALLELE; AREA UNDER THE CURVE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COMORBIDITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG METABOLISM; DRUG UTILIZATION; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; LETTER; MEDICAL LITERATURE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; TREATMENT DURATION; WILD TYPE;

EID: 33846970535     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.285.6.733     Document Type: Letter

References (6)

1. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296:1633-1644.
2. Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA. 2006;296:1653-1656.
3. Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation. 2006;113:1950-1957.
4. Kirchheiner J, Stormer E, Meisel C, Steinbach N, Roots I, Brockmoller J. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics. 2003;13:473-480.
5. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002;54:1257-1270.
6. Stempak D, Bukaveckas BL, Linder M, Koren G, Baruchel S. Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient. Clin Pharmacol Ther. 2005;78:309-310.